Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus.

Sarfaraz A HasniSarthak GuptaMichael DavisElaine PoncioYenealem Temesgen-OyelakinElizabeth JoyalAlice FikeZerai MannaSungyoung AuhYinghui ShiDiana ChanPhilip CarlucciAnn BiehlBarbara DemaNicolas CharlesJames E BalowMeryl WaldmanRichard M SiegelMariana J KaplanJuan Rivera

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2019)

Our findings indicate that omalizumab is well tolerated in SLE and is associated with improvement in disease activity. Larger randomized clinical trials will be needed to assess the efficacy of omalizumab in patients with SLE.

Keyphrases

disease activity
monoclonal antibody
systemic lupus erythematosus
rheumatoid arthritis
rheumatoid arthritis patients
ankylosing spondylitis
juvenile idiopathic arthritis
open label
randomized controlled trial
clinical trial
placebo controlled